MetaCap

Rigel Pharmaceuticals Inc. (RIGL)

NASDAQ: RIGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD

40.09-1.10 (-2.67%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RIGL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$754.89M
EPS (TTM)
$16.07
52-week range
24.95 – 52.61
Day range
39.62 – 41.66
Volume / Avg
352.03K / 248.06K
Beta
—

52-week range

$24.95$52.61

RIGL stock today

On Nov 20, RIGL ended the session at $40.09, shedding $1.10 (2.67%), versus the S&P 500's 3.70% decline. At this level, RIGL sits in the middle of its 52-week range of $24.95 to $52.61: 23.8% below the high, set on Oct 30, 2026 and 60.7% above the low. RIGL is down 6.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 13.3%.

Rigel Pharmaceuticals trades at 2.5x its trailing twelve-month earnings per share of $16.07. Its forward P/E of 8.4x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Rigel Pharmaceuticals

Company profile

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Raul R. Rodriguez
Headquarters
South San Francisco, CA
Employees
172
IPO year
2000
Website
rigel.com

Financial highlights

Full financials

In fiscal 2025, Rigel Pharmaceuticals generated $294.3 million in revenue, up 64.1% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $367.0 million (+1999.1% year over year), for a net margin of 124.7% versus a median of -21.5% in the prior 5 years. Gross margin was 93.3% (up from 89.6%) and operating margin 42.6%.

Rigel Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$294.28M$179.28M$116.88M$120.24M$149.24M
Growth+64.15%+53.38%-2.79%-19.43%+37.39%
Net income$367.02M$17.48M$-25.09M$-58.57M$-17.91M
EPS (diluted)$19.48$0.99$-1.44$-3.44$-0.11

Analyst forecast

Forecast

Consensus (4 analysts)

buy

Avg. price target

$64.40+60.64%

  • Strong buy 0
  • Buy 2
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $47.00High $86.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$1.46 vs $0.87
Surprise
+67.82%

RIGL news

All RIGL news

Rigel Pharmaceuticals peers

Health Care sector
RIGL peer companies
CompanyPrice% ChgMarket capCompare
ARDXArdelyx Inc.2.99-2.29%$751.60Mvs RIGL
IVAInventiva S.A. American Depository Shares3.14-8.99%$750.78Mvs RIGL
ORICOric Pharmaceuticals Inc.7.36-4.42%$764.94Mvs RIGL
COLLCollegium Pharmaceutical Inc.24.72-1.94%$768.18Mvs RIGL
OBXObsidian Therapeutics Inc.12.00-1.23%$741.29Mvs RIGL
IRWDIronwood Pharmaceuticals Inc. Class A4.70-0.21%$778.09Mvs RIGL
SNDXSyndax Pharmaceuticals Inc.8.72-4.49%$785.05Mvs RIGL
VSTMVerastem Inc.6.33-7.73%$797.67Mvs RIGL

Indexes, lists and sector

Rigel Pharmaceuticals stock FAQ

What is Rigel Pharmaceuticals's stock price today?

RIGL last traded at $40.09 as of Nov 20, 4:00 PM EST, down 2.67% on the day. Prices are delayed at least 15 minutes.

Does Rigel Pharmaceuticals pay a dividend?

No. Rigel Pharmaceuticals does not currently pay a regular cash dividend.

What is RIGL's P/E ratio?

RIGL trades at a trailing P/E ratio of 2.49 and a forward P/E of 8.39.

Who is Rigel Pharmaceuticals's CEO?

Mr. Raul R. Rodriguez is the chief executive officer of Rigel Pharmaceuticals Inc., which has about 172 employees.

Has RIGL ever split its stock?

Yes. The most recent RIGL stock split was a 1-for-10 split on Jun 27, 2024, one of 2 splits on record.

What is the RIGL 52-week high?

The 52-week high for RIGL is $52.61 and the 52-week low is $24.95. The stock is currently 23.8% below its high.

Compare RIGL